John Zuris, PhD

Principal at John Zuris Consulting LLC

Speaker

John Zuris is a leading expert in the gene editing and delivery space, specializing in targeted lipid nanoparticle delivery of RNA medicines to extrahepatic tissues. He supports teams across the industry in building their mRNA-LNP discovery platforms, assisting them with CRO and CDMO selection, and strategic planning for generating late-stage preclinical data packages. His current interest is building better delivery vehicles to target T cells for in vivo CAR-T. He was previously the Senior Director of Delivery and Editing Technologies at Editas Medicine, a company focused on using CRISPR gene editing technology to treat patients suffering from severe diseases. John made notable contributions over 10 years to Editas’ ex vivo sickle cell program, Reni-cel, which showed substantial clinical benefit in all patients in the trial, and to a host of in vivo gene editing programs. Prior to joining Editas Medicine, John completed his postdoctoral training in the laboratory of Dr. David Liu, where he developed a lipid nanoparticle delivery system for CRISPR-Cas9 proteins in ex vivo and in vivo applications.